Back to compounds

COMPOUND PROFILE / PROTEINS & BIOLOGICS

Mecasermin / rhIGF-1.

Research draft

Mecasermin is recombinant human IGF-1 used in a regulated prescription product.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

Mecasermin is recombinant human IGF-1 used in a regulated prescription product.

CLASSIFICATIONProteins & biologics
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It activates IGF-1 receptors to support growth in a specific deficiency context.

Human research

Clinical evidence and approval concern defined severe IGF-1 deficiency populations, not healthy-user enhancement.

Preclinical & other research

Growth-factor experiments inform pharmacology but do not broaden eligibility.

Safety & unknowns

Hypoglycaemia and growth-related contraindications require the product label.

Regulatory status

US Increlex has a defined indication. It does not validate IGF-1 LR3 or unidentified IGF preparations.

Reported use & evidence

Research profile draft

The supplied Mecasermin / rhIGF-1 profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds